InnoCare Pharma (STU:33C) Dividend Payout Ratio: 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:33C InnoCare Pharma Ltd STU:33C
78 GF Score
Price €1.51
GF Value €2.29
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Dividend Payout Ratio?

InnoCare Pharma STU:33C -3.21% 78 Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus rates STU:33C with a GF Score™ of 78/100 and a GF Value™ of €2.29 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 130 Biotechnology companies, InnoCare Pharma ranks worse than 769230% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. InnoCare Pharma's Dividend Payout Ratio for the months ended in Dec. 2025 was 0.00.

The historical rank and industry rank for InnoCare Pharma's Dividend Payout Ratio or its related term are showing as below:


STU:33C's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.45
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-08-23), the Dividend Yield % of InnoCare Pharma is 0.00%.

InnoCare Pharma's Dividends per Share for the months ended in Dec. 2025 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


InnoCare Pharma (STU:33C) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


InnoCare Pharma Dividend Payout Ratio Related Terms


InnoCare Pharma Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for InnoCare Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Dividend Payout Ratio Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

STU:33C vs VRTX, REGN, RVMD: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, InnoCare Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCare Pharma Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where InnoCare Pharma's Dividend Payout Ratio falls into.


STU:33C
78GF Score
InnoCare Pharma Ltd STU:33C
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCare Pharma Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

InnoCare Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ 0.046
=0.00

InnoCare Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2025 )/ EPS without NRI (Q: Dec. 2025 )
=0/ 0.049
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
InnoCare Pharma (STU:33C) has a Dividend Payout Ratio of 0.00 as of Dec. 2025. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on InnoCare Pharma and its competitors. According to the industry distribution chart, InnoCare Pharma ranks #999999 out of 130 companies in the Biotechnology industry.
Is InnoCare Pharma's Dividend Payout Ratio too high?
InnoCare Pharma's current Dividend Payout Ratio is 0.00. Based on the distribution chart, InnoCare Pharma ranks #999999 out of 130 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InnoCare Pharma has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Dividend Payout Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #999999 out of 130 companies for Dividend Payout Ratio. This places InnoCare Pharma in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 130 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCare Pharma (STU:33C) is currently considered Possible Value Trap. The stock's GF Value™ is €2.29, compared to a current price of €1.51 — trading 34.1% below its estimated fair value. The current Dividend Payout Ratio is 0.00. InnoCare Pharma's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For InnoCare Pharma (STU:33C), the current Dividend Payout Ratio is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (STU:33C) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of €1.51 is trading 34.1% below its estimated GF Value™ of €2.29. GuruFocus considers InnoCare Pharma to be Possible Value Trap.

Key valuation signals for STU:33C:

  • Dividend Payout Ratio: 0.00
  • GF Value™: €2.29 vs. price of €1.51 (34.1% below fair value)
  • GF Score™: 78/100 with 7 warning signs

No single metric tells the full story. See the STU:33C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InnoCare Pharma Business Description

Other Exchanges 09969:Hong Kong688428:China
Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
78GF Score

Get the complete analysis for STU:33C

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.51
Price
€2.29
GF Value